Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.

You may also be interested in...



Translational R&D Models Like Precompetitive Alliances Needed To Energize Drug Discovery - Indian Symposium

AHMEDABAD, India - Precompetitive collaborations between pharmaceutical companies mainly aimed at identifying biomarkers should intensify further to help weed out undesirable molecules in trials sooner than in expensive Phase II or III studies. Industry-academia alliances are increasingly gravitating in the same direction

Bayer And Cadila Pool Products To Form Equal Stake JV For India Market

MUMBAI - A deal that has been brewing for nearly two years has finally taken a concrete shape. Germany's Bayer Healthcare and India's Zydus Cadila have agreed to form an equal stake company that will see Bayer move its existing sales and marketing business in India to the new enterprise

As Peers Fall To Jaw-dropping Valuations And Sell-off, India's Zydus Cadila Bets On JV To Co-exist

MUMBAI - Large companies with well-oiled manufacturing skills and marketing networks in the growing Indian market have demonstrated their attractiveness as buyout targets for multinational companies, but analysts suggest that there could also be a significant interest developing from both sides of the spectrum in signing up proportionately profitable joint ventures for building strong manufacturing assets

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel